Business Context and Reporting Period
Oncolytics Biotech Inc., a Calgary-based biotechnology company, filed this Form 6-K on November 6, 2008. The company focuses on developing oncolytic viruses, specifically its proprietary formulation REOLYSIN, as potential cancer therapeutics. Its clinical program includes Phase I/II and Phase II human trials using REOLYSIN alone or in combination with radiation or chemotherapy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a media advisory regarding an upcoming conference presentation and does not contain financial statements or quantitative performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document serves solely to announce a corporate presentation event.
Guidance, Outlook, and Risks
Outlook and Events: Dr. Brad Thompson, President and CEO, is scheduled to present a corporate overview at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008, at 11:10 a.m. ET. A live audio webcast and replay will be available on the company's website.
Risks and Forward-Looking Statements: The filing contains forward-looking statements subject to significant risks and uncertainties. Key risks include:
- The efficacy of REOLYSIN as a cancer treatment.
- The success and timely completion of clinical studies and trials.
- Uncertainties related to pharmaceutical research and development.
- Uncertainties related to the regulatory process.
The company cautions investors against placing undue reliance on these statements and does not undertake to update them except as required by law.
Investor Verification Checklist
- Verify the date and time of the Rodman & Renshaw conference presentation (November 11, 2008).
- Review the company's most recent quarterly and annual filings with Canadian and U.S. securities commissions for actual financial data and detailed risk factors.
- Confirm the status of Phase I/II and Phase II clinical trials for REOLYSIN through official regulatory updates.
- Access the live webcast or audio replay via the provided URLs for management commentary.